Please assess the completion status of the following clinical trial:

Trial Title: Western Equine Encephalitis Vaccine, Inactivated

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-55 years of age~* In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations~* Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration~* Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody~* WEE, EEE, VEE, and CHIK PRNT80\<1:10~* Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form~* Be willing to comply with all follow-up visits, testing, and AE reporting~Exclusion Criteria:~* Participant in the USAMRIID SIP~* Receipt of any other vaccine or investigational; drug within 30 days prior to study entry~* Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination~* Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination~* Hypersensitivity to any vaccine~* Allergic to any vaccine component: Human serum albumin, Neomycin~* Receipt of or anticipates receipt of blood products during the study~* Female: Pregnant or breastfeeding~* Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Vaccinated (Type: EXPERIMENTAL): Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)

Based on this trial design, predict the completion outcome and termination type (if applicable).